AJOVY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AJOVY (AJOVY).
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
| Metabolism | Fremanezumab is a monoclonal antibody degraded by general protein catabolism into small peptides and amino acids; no specific metabolic pathways or enzymes are involved. |
| Excretion | Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion. |
| Half-life | Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing. |
| Protein binding | Low level of nonspecific protein binding due to monoclonal antibody structure. Specifically, binding to plasma proteins is negligible (<5%); primarily binds to CGRP receptor with high affinity. |
| Volume of Distribution | Vd at steady state is approximately 7-9 L (0.08-0.11 L/kg for a 70 kg adult), indicating distribution limited to plasma and interstitial space, consistent with a large monoclonal antibody. |
| Bioavailability | Subcutaneous: Absolute bioavailability is 65% (range 55-75%) after SC injection, with peak concentrations reached in 5-7 days. |
| Onset of Action | Subcutaneous: Clinical effect (reduction in monthly migraine days) observed within 1 week after first dose; maximum effect by 3 months. |
| Duration of Action | Duration of action persists for the dosing interval (1 month). After a single dose, effect wanes over several weeks; monthly administration maintains efficacy. |
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment is required for patients with renal impairment, including end-stage renal disease (ESRD) on dialysis. The pharmacokinetics of fremanezumab are not significantly affected by renal function. |
| Liver impairment | No dose adjustment is necessary for patients with hepatic impairment. Fremanezumab is a monoclonal antibody not metabolized by the liver; hepatic function does not alter its pharmacokinetics. |
| Pediatric use | Safety and effectiveness in pediatric patients (<18 years) have not been established. No dosing guidelines are available for pediatric populations. |
| Geriatric use | No specific dose adjustment is recommended for geriatric patients. Clinical studies included limited numbers of patients aged ≥65 years; no overall differences in safety or efficacy were observed compared to younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AJOVY (AJOVY).
| Breastfeeding | Fremanezumab is a large protein that is minimally excreted into breast milk. M/P ratio not determined. IgG molecules are present in colostrum and milk in low concentrations and are digested in infant GI tract. No adverse effects reported. Consider benefits of breastfeeding and maternal need for Ajovy. |
| Teratogenic Risk | Ajovy (fremanezumab) is a humanized monoclonal antibody (IgG2) targeting calcitonin gene-related peptide (CGRP). Based on its mechanism and limited human data, there is no evidence of teratogenicity. Animal studies showed no adverse developmental effects at doses up to 100 mg/kg IV. CGRP is involved in placentation and fetal development; however, IgG crosses the placenta increasingly after first trimester, with highest transfer in third trimester. The risk of major birth defects is considered low but not zero; consider gestational age and benefit-risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to fremanezumab or any excipients in the formulation"]
| Precautions | ["Hypersensitivity reactions (including angioedema, urticaria, rash, pruritus)","Consider discontinuation if serious hypersensitivity occurs","Risk of immune complex formation with long-term use (theoretical)","Caution in patients with history of monoclonal antibody hypersensitivity"] |
| Food/Dietary | None reported. No specific dietary restrictions. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Monitor maternal migraine control and potential adverse effects. No specific fetal monitoring required beyond routine prenatal care. If used near term, consider monitoring for neonatal infections due to potential immunosuppression, though no evidence. |
| Fertility Effects | Animal studies with fremanezumab showed no impairment of fertility in male or female rats at doses up to 100 mg/kg IV. CGRP may have role in reproductive function, but no human data on fertility effects. Likely no significant impact. |
| AJOVY (fremanezumab) is a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP) for migraine prevention. Administer subcutaneously 225 mg monthly or 675 mg quarterly; no dose adjustment needed for renal or hepatic impairment. Injection-site reactions (pain, erythema) are common but typically mild. Avoid in patients with hypersensitivity to rubber (prefilled syringe contains natural rubber latex). Combination with other CGRP antagonists may increase theoretical risk of hypotension; monitor blood pressure if used with antihypertensives. Not recommended for acute migraine treatment. |
| Patient Advice | AJOVY is a preventive migraine medication, not for acute headache relief. · Inject subcutaneously in abdomen, thigh, or upper arm; rotate injection sites to reduce skin reactions. · Store in refrigerator at 2-8°C; do not freeze. Allow to reach room temperature for 30 minutes before injection. · Common side effects include injection-site pain, redness, or swelling; report any signs of allergic reaction (hives, difficulty breathing). · Continue your other migraine medications as prescribed unless advised otherwise by your healthcare provider. · Pregnancy: avoid use unless clearly needed; breastfeeding: caution as it is excreted in human milk. |